WhatsApp Video 2024-10-23 at 3.51.33 PM

Profhilo H+L is the first product of its kind. As a BDDE-free, stabilized, injectable form of hyaluronic acid, this innovative skincare solution works to treat skin laxity. With one of the highest concentrations of hyaluronic acid on the market, it is able to effectively remodel aging and sagging skin tissue.

As a naturally produced substance within the skin, hyaluronic acid hydrates and volumises the tissues of the dermis. When injected into the face, it can be used to add radiance to the complexion and volumise sallow skin.

Profhilo H+L is comprised of 32mg of low-molecular-weight hyaluronic acid and 32 mg of high-molecular-weight hyaluronic acid. The whopping 64mg of hyaluronic acid contained in this unique injectable has set a new high for the industry, working to counteract the age-related loss of hyaluronic acid in the skin in a new and innovative format.

The IBSA Group, a global pharmaceutical company based in Switzerland, manufactures Profhilo H+L out of an FDA-approved site in Italy. Throughout its seven decades in business, this organization has developed a series of highly innovative products, with applications ranging from dermatology to urology.

Each package of Profhilo H+L contains 1 prefilled, 2mL syringe and 2 needles. To reduce chances of premature degradation, it should be stored between 2 and 25°C.

The first BDDE-free, stabilized hyaluronic acid product on the market, Profhilo H+L is used to treat skin laxity and remodel the skin—not just to fill lines and wrinkles. It delivers a dramatic improvement in the quality of facial tissue, helping to give youthful structure and elasticity back to sallow skin.

Profhilo H+L is recommended for use in areas that are commonly affected by skin laxity, including the zygomatic protrusion, tragus, nasal base, chin, and mandibular angle. Doctors use this filler to treat skin laxity in the neck area and inner arms.

Profhilo H+L is neither a dermal filler nor a biorevitaliser—as a bioremodeling product, this innovative solution has opened up an entirely new category of injectables. Made with IBSA’s ultra pure hyaluronic acid, Profhilo H+L is produced through a patented biofermentation process, which results in its unparalleled purity, safety, and tolerance ratings. It also is free of BDDE, which has been found to have mutagenic properties.

Profhilo H+L is formulated based on the concept of Hydrolift Action, an innovative approach that works to counteract the reduction of hyaluronic acid in the skin. Crafted with both low-molecular-weight hyaluronic acid and high-molecular-weight hyaluronic acid, this injectable solution restores skin’s elasticity and tone, deeply hydrating and mechanically lifting the skin at the same time.

Profhilo H+L’s combination of high- and low-molecular-weight hyaluronic acid is made possible due to the use of NAHYCO™ Hybrid Technology. This patented thermal process allows for the creation of a stabilized form of hyaluronic acid—without the use of cross-linking agents like BDDE. As such, this unique formulation is comprised of only pure hyaluronic acid.

What’s more, NAHYCO™ results in increased product longevity. With the hybrid use of high- and low-molecular-weight hyaluronic acid, this cooperative complex is extremely stable when it comes to enzymatic and mechanical degradation. This solution lasts in the skin for approximately 28 days, during which time it stimulates the production of four different types of collagen and elastin. This results in significant tissue improvement, tightening and lifting the skin and features.